Thyroid Function and Non-alcoholic Fatty Liver Disease in Children and Adolescent With Obesity: A Systematic Review and Meta-Analysis.

Endocr PractApr 9, 2026 (epub)

Elisa Gatta, Massimiliano Ugoccioni, Elena Gandossi et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review and meta-analysis examined thyroid function in children and adolescents with obesity, comparing those with and without non-alcoholic fatty liver disease (NAFLD). Ten observational studies included 5,145 participants. Across six studies (3,076 participants), TSH was higher in the NAFLD group, with a mean difference of 0.37 mIU/L (95% CI 0.07-0.66). Free thyroxine and free triiodothyronine did not differ significantly between groups. The findings indicate an association between NAFLD and higher TSH, but do not establish causality.

Key findings

  • Across six studies (n= 3076), TSH was higher with NAFLD: mean difference 0.37 mIU/L; 95% CI 0.07-0.66.
  • Free thyroxine did not differ significantly between groups (standardized mean difference -0.35; 95% CI -1.15 to 0.45).
  • Free triiodothyronine did not differ significantly between groups (standardized mean difference 0.35; 95% CI -0.26 to 0.96).
  • The TSH association was robust in sensitivity analyses; heterogeneity was moderate (I 2 = 48.7%).

Why it matters

In children and adolescents with obesity, higher TSH may accompany hepatic steatosis even when circulating thyroid hormone concentrations are not significantly different. This association may help frame interpretation of thyroid tests in this population, but the evidence does not show that TSH causes NAFLD or establish its value for diagnosis or management.

What to keep in mind

The evidence comes from observational studies, so it cannot establish causality. The authors note that prospective studies are needed to clarify clinical implications.

Source

Published in Endocr Pract. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Endocrinology

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.